MOTS-c

MOTS-c (Mitochondrial Open Reading Frame of the Twelve S rRNA type-c) is a 16-amino acid mitochondrial-derived peptide encoded in the 12S rRNA gene of mitochondrial DNA. Discovered in 2015 by Dr. Pinchas Cohen's laboratory at USC, MOTS-c was the first mitochondrial-encoded peptide shown to have profound metabolic effects — functioning as an exercise mimetic that enhances insulin sensitivity, promotes fat oxidation, and improves metabolic homeostasis. MOTS-c's discovery expanded the concept of mitochondrial-derived peptides (MDPs) as a new class of signaling molecules. Remarkably, MOTS-c translocates to the nucleus during metabolic stress, directly regulating gene expression — the first example of a mitochondrial-encoded peptide acting as a nuclear transcription regulator. It declines with age, suggesting a role in age-related metabolic dysfunction.

MOTS-c activates AMPK (the master energy sensor) by increasing the AMP/ATP ratio through inhibition of the folate/methionine cycle (reducing de novo purine synthesis). Activated AMPK enhances fatty acid oxidation, glucose uptake, and mitochondrial biogenesis. Uniquely, MOTS-c translocates to the nucleus during metabolic stress, where it interacts with ARE (antioxidant response element) regulators and modulates stress-responsive gene expression. It enhances skeletal muscle glucose uptake independently of insulin through AMPK-mediated GLUT4 translocation.

Exercise Mimetic MOTS-c reproduces many metabolic effects of exercise: enhanced fat oxidation, improved insulin sensitivity, increased mitochondrial function. Research positions it as a potential treatment for sedentary-related metabolic disease. Type 2 Diabetes and Insulin Resistance Preclinical studies show MOTS-c restores insulin sensitivity in diet-induced obesity models, reduces fasting glucose, and improves glucose tolerance — effects comparable to exercise intervention. Aging and Longevity MOTS-c levels decline with age. Supplementation in aged mice improves physical performance, metabolic health, and healthspan, suggesting potential anti-aging applications. Obesity MOTS-c prevents diet-induced obesity in animal models through enhanced energy expenditure and fat oxidation, without reducing food intake. Osteoporosis Recent research shows MOTS-c promotes osteoblast differentiation and bone formation through AMPK-dependent pathways.

AMPK activation through metabolic shift (folate cycle inhibition). AMPK/ACC/CPT-1 for fat oxidation. AMPK/GLUT4 for insulin-independent glucose uptake. Nuclear translocation for ARE-mediated gene regulation. PGC-1α for mitochondrial biogenesis.

Limited human safety data as MOTS-c is primarily in preclinical research. No significant toxicity in animal studies. Theoretical risk of excessive AMPK activation affecting cellular energy balance. Potential for hypoglycemia in combination with diabetes medications.

MOTS-c is supplied as lyophilized powder. Store at -20°C for long-term stability. Reconstitute with bacteriostatic water or sterile saline. Use within 21 days at 2-8°C. In-vivo half-life is relatively short, necessitating daily or frequent administration.

Investigational. Preclinical and early translational research. Not approved by any regulatory authority. Not WADA-prohibited (but classification may evolve as clinical development progresses).